drugset / Trial / NCT00169988
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
Completed
8 enrolled
Northwell Health
Janssen Pharmaceutica N.V., Belgium · collabPfizer · collabStanley Medical Research Institute · collab
RandomizedParallel-groupQuadruple-blindDiagnostic
Summary
The Recognition and Prevention (RAP) Program is conducting a research study comparing an antidepressant, sertraline, alone versus in combination with a second-generation antipsychotic, risperidone, to evaluate their ability to reduce unusual thoughts, suspiciousness and other unusual experiences, to improve reasoning ability, memory, attention and social skills in adolescents.
Timeline
- Start
- 2004-03
- Primary completion
- —
- Completion
- 2007-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Risperidone | Other / unclassified | — | — |
| Subject | Sertraline | Small molecule | — | — |